KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non Operating Income: 2020-2025

Historic Non Operating Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $10.0 million.

  • Recursion Pharmaceuticals' Non Operating Income rose 271.48% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 29.82%. This contributed to the annual value of $14.2 million for FY2024, which is 20.72% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Non Operating Income stood at $10.0 million, which was up 129.84% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Non Operating Income ranged from a high of $10.0 million in Q3 2025 and a low of -$11.3 million during Q1 2025.
  • For the 3-year period, Recursion Pharmaceuticals' Non Operating Income averaged around $3.2 million, with its median value being $4.3 million (2025).
  • Its Non Operating Income has fluctuated over the past 5 years, first spiked by 226,800.00% in 2023, then plummeted by 369.27% in 2025.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Non Operating Income stood at $27,000 in 2021, then surged by 12,825.93% to $3.5 million in 2022, then plummeted by 46.36% to $1.9 million in 2023, then spiked by 160.10% to $4.9 million in 2024, then soared by 271.48% to $10.0 million in 2025.
  • Its Non Operating Income was $10.0 million in Q3 2025, compared to $4.3 million in Q2 2025 and -$11.3 million in Q1 2025.